Affymax (Affymax) ROCE % : 2,035.00% (As of Jun. 2014)

View and export this data going back to 2006. Start your Free Trial

What is Affymax ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Affymax's annualized ROCE % for the quarter that ended in Jun. 2014 was 2,035.00%.

Affymax ROCE % Historical Data

The historical data trend for Affymax's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax ROCE % Chart

Affymax Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

ROCE %

Get a 7-Day Free Trial

-102.31

-17.25

-67.11

-156.15

-169.55

Affymax Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
ROCE %	Get a 7-Day Free Trial															3,333.22	-97.13	-231.60	-	2,035.00

Affymax ROCE % Calculation

Affymax's annualized ROCE % for the fiscal year that ended in Dec. 2013 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2013 )		(A: Dec. 2012 )		(A: Dec. 2013 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2013 )		(A: Dec. 2012 )		(A: Dec. 2013 )
	=	-15.017	/	( ( (118.217 - 99.075)	+	(7.443 - 8.871) )	/ 2 )
	=	-15.017	/	( (19.142	+	-1.428)	/ 2 )
	=	-15.017	/	8.857
	=	-169.55 %

Affymax's ROCE % of for the quarter that ended in Jun. 2014 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2014 )		(Q: Mar. 2014 )		(Q: Jun. 2014 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2014 )		(Q: Mar. 2014 )		(Q: Jun. 2014 )
	=	28.836	/	( ( (6.463 - 8.799)	+	(5.384 - 0.214) )	/ 2 )
	=	28.836	/	( ( -2.336	+	5.17 )	/ 2 )
	=	28.836	/	1.417
	=	2,035.00 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2014) EBIT data.

Affymax (OTCPK:AFFY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Affymax ROCE % Related Terms

Thank you for viewing the detailed overview of Affymax's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax (Affymax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Executives

John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson	officer: Chief Financial Officer	8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp	officer: Chief Commercial Officer	4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte	director
Karin L Walker	officer: VP, Finance & CAO	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton	director
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland	officer: EVP, Corp. Development and CFO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris	director, officer: CEO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor • 05-19-2010

AFFYMAX, INC. Reports Operating Results (10-Q)

By gurufocus • 08-05-2009

AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares

By GuruFocus Research GuruFocus Editor • 02-26-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor • 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares

By gurufocus • 09-03-2009

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor • 09-30-2009